Jenburkt Pharmaceuticals Limited

BSE:524731 Stock Report

Market Cap: ₹5.5b

Jenburkt Pharmaceuticals Management

Management criteria checks 3/4

Jenburkt Pharmaceuticals' CEO is Ashish Bhuta, appointed in Jul 2013, has a tenure of 11.42 years. total yearly compensation is ₹22.27M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 7.08% of the company’s shares, worth ₹380.51M. The average tenure of the management team and the board of directors is 13.6 years and 3.1 years respectively.

Key information

Ashish Bhuta

Chief executive officer

₹22.3m

Total compensation

CEO salary percentage100.0%
CEO tenure11.4yrs
CEO ownership7.1%
Management average tenure13.6yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ashish Bhuta's remuneration changed compared to Jenburkt Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹303m

Jun 30 2024n/an/a

₹280m

Mar 31 2024₹22m₹22m

₹260m

Dec 31 2023n/an/a

₹244m

Sep 30 2023n/an/a

₹245m

Jun 30 2023n/an/a

₹240m

Mar 31 2023₹20m₹20m

₹246m

Dec 31 2022n/an/a

₹217m

Sep 30 2022n/an/a

₹225m

Jun 30 2022n/an/a

₹236m

Mar 31 2022₹17m₹17m

₹223m

Dec 31 2021n/an/a

₹227m

Sep 30 2021n/an/a

₹224m

Jun 30 2021n/an/a

₹201m

Mar 31 2021₹15m₹15m

₹165m

Dec 31 2020n/an/a

₹172m

Sep 30 2020n/an/a

₹159m

Jun 30 2020n/an/a

₹158m

Mar 31 2020₹17m₹17m

₹149m

Dec 31 2019n/an/a

₹171m

Sep 30 2019n/an/a

₹170m

Jun 30 2019n/an/a

₹172m

Mar 31 2019₹15m₹15m

₹198m

Dec 31 2018n/an/a

₹185m

Sep 30 2018n/an/a

₹186m

Jun 30 2018n/an/a

₹228m

Mar 31 2018₹13m₹11m

₹172m

Compensation vs Market: Ashish's total compensation ($USD261.57K) is above average for companies of similar size in the Indian market ($USD42.37K).

Compensation vs Earnings: Ashish's compensation has been consistent with company performance over the past year.

CEO

Ashish Bhuta (51 yo)

11.4yrs

Tenure

₹22,265,000

Compensation

Mr. Ashish Uttam Bhuta has been the Chairman and Managing Director of Jenburkt Pharmaceuticals Ltd. since July 16, 2013. Mr. Bhuta served as a Whole-Time Director of Jenburkt Pharmaceuticals from June 2, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Ashish Bhuta
Chairman & MD11.4yrs₹22.27m7.08%
₹ 388.1m
Dilip Bhuta
CFO & Whole Time Directorno data₹6.57m0.014%
₹ 745.7k
Ashish Shah
Compliance Officer & Company Secretaryno data₹4.72mno data
Bhanudas Kadam
Head of QA/QCno datano datano data
Jayesh Tanna
Head of Information Technology27.4yrsno datano data
Barani Sivaprakasam
Head of Sales (Wellness Division)1.7yrsno datano data
Uday Kalele
Head of R&D and Projects at Plant15.8yrsno datano data
Vinay Bhatt
Head of International Businessno datano datano data
Seshachalam Janakiraman
Head of Sales & Marketing Pharmaceutical Vertical (India)no datano datano data
Mahender Singh
Head of Sales & Marketing (Brenz Division)no datano datano data

13.6yrs

Average Tenure

59yo

Average Age

Experienced Management: 524731's management team is seasoned and experienced (13.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ashish Bhuta
Chairman & MD17.5yrs₹22.27m7.08%
₹ 388.1m
Dilip Bhuta
CFO & Whole Time Director11.4yrs₹6.57m0.014%
₹ 745.7k
Pankaj Dantwala
Non-Executive Independent Directorless than a yearno datano data
Hina Mehta
Non-Executive Independent Director4.8yrs₹100.00kno data
Sumit Thakkar
Non-Executive Independent Director1.4yrs₹75.00kno data
Krishnan Subharaman
Non-Executive Independent Directorless than a yearno datano data

3.1yrs

Average Tenure

62yo

Average Age

Experienced Board: 524731's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:19
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jenburkt Pharmaceuticals Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research